CJC-1295 (No DAC): Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 8 sources cited
Overview
CJC-1295 without DAC, also known as Modified GRF(1-29) or Mod GRF, is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile growth hormone release from the anterior pituitary. It is the most widely used GHRH analog in peptide therapy, prized for producing physiological GH pulses that mimic the body's natural secretory pattern. Its half-life has never been measured in people, while the DAC version's is 5.8 to 8.1 days; the related D-Ala2 analog of GHRH(1-29) cleared with a half-time of 6.7 minutes in men, against 4.3 minutes for the unmodified fragment. Almost always paired with a GHRP — typically Ipamorelin — for dramatically amplified GH output.
Mechanism of Action
CJC-1295 (no DAC) is a modified version of the first 29 amino acids of endogenous GHRH, with four amino acid substitutions at positions 2, 8, 15, and 27 (Ala², Glu⁸, Ala¹⁵, Leu²⁷). These substitutions were strategically designed to protect the peptide from enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), the enzyme that rapidly degrades native GHRH, which cleared with a half-time of 4.3 minutes in men. Analogs carrying a D-amino acid at position 2 resist DPP-IV cleavage in vitro, and in the one human study of such an analog the half-time rose to 6.7 minutes; the four-substitution peptide itself has never been measured in people. **Receptor pharmacology:** Mod GRF binds to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary. The GHRH-R is a Class B G-protein coupled receptor (GPCR) that signals primarily through Gαs, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates transcription factors (CREB) that increase GH gene transcription AND triggers exocytosis of stored GH granules for immediate release. **The GHRH + GHRP synergy:** When Mod GRF is combined with a GHRP (growth hormone-releasing peptide) like Ipamorelin, the GH pulse amplitude is amplified beyond what either peptide produces alone. This occurs because GHRPs work through a completely different receptor (the ghrelin/GHS receptor, GHS-R1a) using different intracellular signaling (Gαq → IP3/calcium rather than Gαs → cAMP). The two signaling cascades converge synergistically on GH release. Additionally, GHRPs suppress somatostatin (the GH-inhibiting hormone), removing the brake while Mod GRF steps on the gas. **Advantages over exogenous GH:** Because Mod GRF stimulates endogenous GH production, the resulting GH has the full spectrum of normal GH isoforms and follows physiological pulsatile timing. This preserves the negative feedback mechanisms that prevent excessive IGF-1 elevation, avoids GH receptor desensitization, and maintains the body's natural regulatory capacity. Exogenous GH, by contrast, provides only the 22kDa isoform in a non-pulsatile pattern and suppresses endogenous GH production through direct negative feedback.
CJC-1295 (No DAC) Benefits: What the Research Shows
- GHRH combined with a GHRP produces synergistic GH release in men, well above either peptide alone, though no study has tested the four-substitution analog itself
- GH pulsatility has not been measured on this peptide; with the DAC version, pulse frequency and amplitude were unchanged while trough GH rose 7.5-fold, which is sustained elevation rather than a pulse
- There are no clinical studies of this peptide; in the DAC version's healthy-volunteer studies, injection site reactions occurred in about 70% of subjects and headache in 63%, with no consistent change in glucose
- No IGF-1 data exist for this peptide; a single dose of the DAC version raised IGF-I 1.5 to 3 fold for 9 to 11 days in one study and by 44% at one week in another
- The DPP-IV-resistant design is supported in vitro, where GRF analogs with a D-amino acid at position 2 were not cleaved, and in men, where the D-Ala2 substitution lengthened the half-time from 4.3 to 6.7 minutes
- Ipamorelin is the preferred GHRP partner because, in rats and swine, it released GH without the ACTH and cortisol rises seen with GHRP-2 and GHRP-6
CJC-1295 (No DAC) Dosage
- Standard dose: 100 mcg (1 mcg/kg for a 100 kg individual) subcutaneous injection, combined with Ipamorelin 100–200 mcg at each injection. This combination is the foundation of modern peptide-based GH therapy.
- Dosing frequency: 1–3 times daily. Common protocols: (1) Once daily at bedtime to amplify the nocturnal GH surge; (2) Twice daily — morning and bedtime; (3) Three times daily — morning, post-workout, and bedtime for maximum GH output.
- Critical timing: Inject on an empty stomach — at least 2 hours after eating, and wait at least 30 minutes before eating after injection. Elevated insulin and blood glucose directly suppress GH release, negating the peptide's effects. This is the most common mistake users make.
- Bedtime dosing is particularly effective because it synergizes with the natural nocturnal GH pulse. The largest endogenous GH secretion occurs during the first 90 minutes of deep sleep (Stage 3 NREM). Injecting 15–30 minutes before bed amplifies this peak.
- Post-workout timing: Inject within 15 minutes of completing resistance training to synergize with the exercise-induced GH pulse. Wait at least 30 minutes before consuming a post-workout meal.
- Cycle: 12–16 weeks on, 4 weeks off. Some practitioners run continuous protocols at once-daily dosing without cycling, as the pulsatile nature of Mod GRF preserves pituitary sensitivity. However, periodic breaks are recommended to prevent potential pituitary desensitization.
- Saturation dose: The GHRH receptor saturates at approximately 100 mcg — doses above this do not proportionally increase GH output. Using 200 mcg produces only marginally more GH than 100 mcg, making higher doses cost-inefficient.
- Do NOT combine with food, sugar, or carbohydrates. Even a small insulin spike will significantly blunt the GH response.
- Reconstitution: Add 2 mL bacteriostatic water to a 5 mg vial = 2.5 mg/mL (100 mcg per 0.04 mL/4 units on an insulin syringe).
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
CJC-1295 (No DAC) Side Effects & Safety
Known Side Effects
- Injection site reactions — mild redness, itching, or transient pain. Common but minor. Rotate injection sites.
- Flushing and warmth — a sensation of warmth or facial flushing within 5–10 minutes of injection, reported by approximately 15–20% of users. Caused by vasodilation from GH release. Temporary and harmless.
- Head rush or lightheadedness — transient dizziness within minutes of injection, particularly at higher doses. Usually mild and self-resolving within 15 minutes.
- Increased hunger — GH stimulates appetite in some individuals. More pronounced with GHRP-6 combinations than with Ipamorelin.
- Water retention — mild fluid retention, particularly in the hands and feet, more common during the first 2 weeks. Usually resolves as the body adjusts. Much less pronounced than with exogenous GH.
- Tingling or numbness in extremities — related to GH-mediated fluid shifts. Typically transient.
- Vivid dreams — commonly reported, likely related to enhanced deep sleep quality from the nocturnal GH surge. Generally considered a positive effect.
- Fatigue initially — some users feel more tired in the first week as sleep architecture deepens. Transitions to improved energy as the body adapts.
Safety Profile
CJC-1295 (no DAC) has no clinical safety data at all: FDA's 2024 review found no pharmacological or clinical studies of the substance and recommended against allowing it in pharmacy compounding, noting that the DAC version's profile cannot be extrapolated to it. Its pulsatile mechanism preserves the body's natural GH regulatory systems, including somatostatin negative feedback, which prevents the excessive IGF-1 elevation associated with exogenous GH. No study has measured glucose tolerance on this peptide; in the DAC version's volunteer studies there were no consistent changes in glucose. The key safety advantages over exogenous GH include: preserved pulsatile release pattern, maintained endogenous production capacity (GH production recovers quickly upon cessation), no antibody formation against endogenous GH, lower risk of carpal tunnel syndrome and other GH side effects, and self-limiting effects (the pituitary has a finite releasable GH pool per pulse, providing a natural ceiling). Contraindications include: active malignancy (GH/IGF-1 can promote tumor growth), history of pituitary tumors, uncontrolled diabetes (GH opposes insulin action), and pregnancy/breastfeeding. Individuals over 40 should have baseline IGF-1 levels checked, and periodic monitoring (every 3–6 months) is recommended during use. Do not combine with exogenous GH (redundant and potentially suppressive). Caution in individuals with a history of cancer — allow adequate cancer-free interval before using any GH-promoting therapy.
What to Expect
Week 1: Improved sleep quality is typically the first noticeable effect — deeper sleep, easier falling asleep, and more vivid dreams. Mild flushing after injection is common. Some users notice a subtle energy improvement by the end of the first week. Weeks 2–4: Sleep quality continues to improve. Recovery from exercise accelerates noticeably. Skin texture begins improving (smoother, better hydration). Mild fat loss may begin, particularly with proper diet and exercise. Nails may grow faster. Weeks 5–8: Body composition changes become visible — reduced abdominal fat, improved muscle tone, better workout recovery. Energy and mood are consistently improved. Hair quality may improve. Joint comfort often increases as GH promotes connective tissue health. IGF-1 levels typically increase 50–100% above baseline when measured. Weeks 9–12: Full effects are established. Users report looking and feeling younger — improved skin elasticity, body composition, energy, sleep, and recovery. These effects are cumulative and build throughout the cycle. Fat loss and muscle definition continue to improve. Weeks 13–16+: Continued benefits with maintenance dosing. Upon cycling off, most effects gradually diminish over 2–4 weeks as GH and IGF-1 return to baseline. Sleep quality and skin improvements tend to persist longest.
Common Stacks
Ipamorelin
The gold-standard combination. Ipamorelin provides ghrelin-receptor-mediated GH release that synergizes with Mod GRF's GHRH-receptor activation, amplifying GH pulses 7–10x. Ipamorelin is preferred over GHRP-2/6 for its clean side effect profile (no cortisol, prolactin, or hunger increase).
AOD-9604
AOD-9604 provides targeted fat loss that complements the body composition benefits of enhanced GH output from CJC/Ipa. Morning AOD + bedtime CJC/Ipa covers fat loss and recovery in a complementary protocol.
BPC-157
BPC-157 upregulates GH receptors, and CJC-1295/Ipamorelin increases GH output — creating a powerful synergy where more GH is produced AND tissues are more responsive to it. Excellent for injury recovery.
Storage & Handling
Store lyophilized powder refrigerated at 36–46°F (2–8°C). Can be frozen at -4°F (-20°C) for long-term storage (24+ months). After reconstitution with bacteriostatic water, refrigerate at 36–46°F and use within 4–6 weeks. Typical reconstitution: 2 mL bacteriostatic water to a 5 mg vial (2.5 mg/mL). Gently swirl to dissolve — do not shake. Do not freeze reconstituted solution. Keep reconstituted vials upright in the refrigerator. CJC-1295 is relatively stable as peptides go, but prolonged exposure to heat or light degrades potency.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- FDA Briefing Document, Pharmacy Compounding Advisory Committee: evaluation of five CJC-1295-related bulk drug substances for the 503A Bulk Drug Substances List. U.S. Food and Drug Administration. 2024.
- Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994.
- Bongers J, Lambros T, Ahmad M, et al. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta. 1992.
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006.
- Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
- Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999.
CJC-1295 Dosage Guide
Read the full guideRelated Peptides
Track CJC-1295 (No DAC) in Your Protocol
Log your CJC-1295 (No DAC) doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free